$4.58
3.48% today
Nasdaq, Apr 04, 08:47 pm CET
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Ardelyx, Inc. Stock price

$4.74
-0.34 6.69% 1M
-1.92 28.83% 6M
-0.33 6.51% YTD
-2.61 35.51% 1Y
+3.57 305.13% 3Y
-1.01 17.57% 5Y
-8.28 63.59% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.14 2.87%
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Key metrics

Market capitalization $1.13b
Enterprise Value $1.03b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.10
P/S ratio (TTM) P/S ratio 3.39
P/B ratio (TTM) P/B ratio 6.51
Revenue growth (TTM) Revenue growth 168.06%
Revenue (TTM) Revenue $333.62m
EBIT (operating result TTM) EBIT $-27.95m
Free Cash Flow (TTM) Free Cash Flow $-45.82m
Cash position $250.10m
EPS (TTM) EPS $-0.17
P/E forward negative
P/S forward 3.01
EV/Sales forward 2.75
Short interest 14.47%
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Ardelyx, Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Ardelyx, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
334 334
168% 168%
100%
- Direct Costs 53 53
152% 152%
16%
281 281
171% 171%
84%
- Selling and Administrative Expenses 257 257
100% 100%
77%
- Research and Development Expense 50 50
47% 47%
15%
-26 -26
56% 56%
-8%
- Depreciation and Amortization 2.06 2.06
48% 48%
1%
EBIT (Operating Income) EBIT -28 -28
56% 56%
-8%
Net Profit -39 -39
41% 41%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that an abstract detailing a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), was a...
Neutral
GlobeNewsWire
22 days ago
Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy
Neutral
Seeking Alpha
about one month ago
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, providing investment ideas and sparking discussions on their potential. Edtech company Udemy is seen as on the rise and is a Strong Buy from Weebler Finance. Jumia Technologies shows resilience and growth potential in African e-commerce, despite market skepticism and low stock prices.
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 395
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today